Novel Peptide for ALI
Acute Lung Injury (ALI)
Pre-clinicalActive
Key Facts
About Peroxitech
Founded in 2016, Peroxitech is a preclinical-stage biotech targeting acute lung injury and related conditions through a novel peptide technology. The company's science is based on foundational research from the University of Pennsylvania's Institute for Environmental Medicine, co-invented by its scientific founders. With recent NIH grant funding for both ALI and lung transplant organ viability, Peroxitech is advancing its lead program while exploring adjacent applications in critical care and transplantation. The leadership combines deep pulmonary disease expertise with pharmaceutical industry experience in operations and commercialization.
View full company profileTherapeutic Areas
Other Acute Lung Injury (ALI) Drugs
| Drug | Company | Phase |
|---|---|---|
| Vitamin A Palmitate Platform | Advent Therapeutics | Unknown |